Payment overview · 2025
General Payments
$1,377.00
42 reported records · 12 companies
Healthcare provider profile · identity verified
Denise Mcglothlin, ARNP, FNP-BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LEHIGH ACRES, FL · NPI 1306083423
Verified facts
What the public records show
CMS Open Payments records show Denise Mcglothlin, ARNP, FNP-BC received $1,377.00 in general payments during 2025 across 42 reported records.
ConvaTec Inc. accounted for 50.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $690.49 | 50.1% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $185.52 | 13.5% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $153.34 | 11.1% | 9 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $104.79 | 7.6% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $62.47 | 4.5% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $50.36 | 3.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.61 | 2.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.81 | 1.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.21 | 1.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.72 | 1.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.20 | 1.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.48 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,096.87 | 41 |
| Travel and Lodging | $280.13 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INNOVAMATRIX AC Normalized: innovamatrix ac |
Device | ConvaTec Inc. | $690.49 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $118.67 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $97.83 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $91.78 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $90.97 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $76.88 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $55.51 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $50.36 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $41.64 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $41.64 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.61 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.61 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $27.91 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.88 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 48 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 453 | 142 |
| Levothyroxine Sodium | Levothyroxine Sodium | 363 | 92 |
| Lisinopril | Lisinopril | 300 | 88 |
| Omeprazole | Omeprazole | 246 | 71 |
| Alprazolam | Alprazolam | 245 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 236 | 78 |
| Ezetimibe | Ezetimibe | 155 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 155 | 52 |
| Naproxen | Naproxen | 142 | 54 |
| Metformin Hcl | Metformin Hcl | 137 | 48 |
| Methylprednisolone | Methylprednisolone | 132 | 104 |
| Glipizide | Glipizide | 128 | 47 |
| Tizanidine Hcl | Tizanidine Hcl | 124 | 72 |
| Tramadol Hcl | Tramadol Hcl | 118 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 117 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 113 | 43 |
| Fenofibrate | Fenofibrate | 112 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 37 |
| Losartan Potassium | Losartan Potassium | 97 | 30 |
| Gabapentin | Gabapentin | 95 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 91 | 28 |
| Furosemide | Furosemide | 87 | 31 |
| Famotidine | Famotidine | 86 | 31 |
| Lovastatin | Lovastatin | 84 | 25 |
| Azithromycin | Azithromycin | 83 | 54 |
| Montelukast Sodium | Montelukast Sodium | 81 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 80 | 29 |
| Alendronate Sodium | Alendronate Sodium | 78 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 22 |
| Lorazepam | Lorazepam | 69 | 16 |
| Carvedilol | Carvedilol | 68 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 67 | 25 |
| Potassium Chloride | Potassium Chloride | 61 | 23 |
| Eliquis | Apixaban | 52 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 13 |
| Mounjaro | Tirzepatide | 48 | 13 |
| Trazodone Hcl | Trazodone Hcl | 47 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 46 | 15 |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Allopurinol | Allopurinol | 42 | 12 |
| Ozempic | Semaglutide | 41 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 12 |
| Torsemide | Torsemide | 41 | 16 |
| Jardiance | Empagliflozin | 40 | 15 |
| Sertraline Hcl | Sertraline Hcl | 40 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 37 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Prednisone | Prednisone | 36 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 32 | 11 |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Ketoconazole | Ketoconazole | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 13 |
| Atenolol | Atenolol | 28 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 27 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 24 |
| Venlafaxine Hcl | Venlafaxine Hcl | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 21 |
| Finasteride | Finasteride | 25 | suppressed |
| Meloxicam | Meloxicam | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 23 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Nystatin | Nystatin | 23 | 17 |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Mupirocin | Mupirocin | 22 | 18 |
| Temazepam | Temazepam | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 13 |
| Cephalexin | Cephalexin | 21 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 20 | suppressed |
| Simvastatin | Simvastatin | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | 14 |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,377.00 · 42 records | ConvaTec Inc. | AIRSUPRA, BREZTRI, CAPVAXIVE, Cologuard Collection Kit, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, INNOVAMATRIX AC, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error